Skip to main content
. 2022 Jun 23;12:833093. doi: 10.3389/fonc.2022.833093

Figure 2.

Figure 2

Adjuvant systemic therapy by molecular markers status among 330 patients with at least two invasive tumor foci. Adjuvant endocrine therapy (A), anti-HER2 therapy (B), and chemotherapy (C) by molecular markers status. (D) Adjuvant endocrine therapy by HR status. (E) Adjuvant anti-HER2 therapy by HER2 status.